Neurogene Inc. Files Q3 2024 10-Q
Ticker: NGNE · Form: 10-Q · Filed: Nov 18, 2024 · CIK: 1404644
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, filing-update
TL;DR
Neurogene Inc. 10-Q filed. Q3 2024 update.
AI Summary
Neurogene Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Neoleukin Therapeutics, Inc., is focused on pharmaceutical preparations. Key financial details and historical company name changes are noted in the filing.
Why It Matters
This filing provides investors with an update on Neurogene Inc.'s financial performance and operational status for the third quarter of 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Neurogene Inc. faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 0.25 — Shares (Indicates a share value or ratio, though specific context is limited in the provided snippet.)
Key Players & Entities
- Neurogene Inc. (company) — Filer of the 10-Q
- Neoleukin Therapeutics, Inc. (company) — Former name of Neurogene Inc.
- 20240930 (date) — End of the reporting period
- 20241118 (date) — Filing date
FAQ
What is the primary business of Neurogene Inc.?
Neurogene Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
When was the company formerly known as Neoleukin Therapeutics, Inc.?
The company changed its name from Neoleukin Therapeutics, Inc. on August 12, 2019.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending September 30, 2024.
What is the filing date of this 10-Q?
This 10-Q was filed on November 18, 2024.
What are some of the historical names of Neurogene Inc.?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, and AQUINOX PHARMACEUTICALS (USA) INC.
Filing Stats: 4,813 words · 19 min read · ~16 pages · Grade level 16.9 · Accepted 2024-11-18 17:27:10
Key Financial Figures
- $0.000001 — ich registered Common stock, par value $0.000001 per share NGNE The Nasdaq Global Mark
Filing Documents
- ngne-20240930.htm (10-Q) — 1596KB
- ngne-2024formq310xqxex101.htm (EX-10.1) — 82KB
- ngne-2024formq310xqxex311p.htm (EX-31.1) — 9KB
- ngne-2024formq310xqxex312p.htm (EX-31.2) — 9KB
- ngne-2024formq310xqxex321.htm (EX-32.1) — 7KB
- ngne-20240930_g1.jpg (GRAPHIC) — 91KB
- ngne-20240930_g2.jpg (GRAPHIC) — 96KB
- 0001404644-24-000104.txt ( ) — 7467KB
- ngne-20240930.xsd (EX-101.SCH) — 45KB
- ngne-20240930_cal.xml (EX-101.CAL) — 67KB
- ngne-20240930_def.xml (EX-101.DEF) — 192KB
- ngne-20240930_lab.xml (EX-101.LAB) — 604KB
- ngne-20240930_pre.xml (EX-101.PRE) — 425KB
- ngne-20240930_htm.xml (XML) — 803KB
Financial Statements
Financial Statements 1 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.
Controls and Procedures
Controls and Procedures 38 Part II Other Information 39 Item 1.
Legal Proceedings
Legal Proceedings 39 Item 1A.
Risk Factors
Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 79 Item 3. Defaults Upon Senior Securities 79 Item 4. Mine Safety Disclosures 79 Item 5. Other Information 79 Item 6. Exhibits 80
Signatures
Signatures 81 Table of Contents
- Financial Information
Part I - Financial Information
Condensed Financial Statements
Item 1. Condensed Financial Statements Neurogene Inc. Condensed Consolidated Balance Sheets (In Thousands, Except Share Information) (Unaudited) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 66,633 $ 148,210 Short-term investments 72,360 48,947 Prepaid expenses and other current assets 4,654 3,191 Total current assets 143,647 200,348 Property and equipment, net 16,068 17,174 Operating lease right-of-use assets 3,193 3,681 Finance lease right-of-use assets 84 98 Restricted cash 339 508 Other non-current assets 789 764 Total assets $ 164,120 $ 222,573 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,684 $ 2,596 Accrued expenses and other current liabilities 10,438 17,495 Operating lease liabilities, current 2,856 2,559 Finance lease liabilities, current 54 42 Contingent value rights liability, current 768 281 Total current liabilities 15,800 22,973 Operating lease liabilities, non-current 10,170 12,302 Finance lease liabilities, non-current 39 65 Contingent value rights liability, non-current 646 1,006 Other liabilities 51 203 Total liabilities 26,706 36,549 Stockholders' equity: Preferred stock, $ 0.000001 par value; 50,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023 — — Common stock, $ 0.000001 par value; 450,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 13,010,867 and 12,823,665 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively — — Additional paid-in capital 380,198 373,178 Accumulated deficit ( 242,784 ) ( 187,154 ) Total stockholders' equity 137,414 186,024 Total liabilities and stockholders' equity $ 164,120 $ 222,573 The accompanying notes are an integral part of these condensed consolidated financial statements. -1- Table of Contents Neurogene Inc. Condensed Consolidate